This is a lot of speculation and no substance. In pharma, nothing leaves the door without meeting release specs. Every batch is tested, every incoming material is tested, every manufacturing suite is tested, and so on. You can't simply make up the release requirements on the fly either, because it's part of the batch record ("recipe") for the drug, and that's on file with the FDA. It's extremely unlikely that lots all labeled as the same drug product went out the door with entirely different contents.

We also lack data on any of the lots mentioned, which can influence these statistics. Was each lot fully administered, or were some underutilized? Drug product is sometimes lost in distribution (for example, it expires), in which case it's sent to destruction. What about lot sizes, were these all the same? Yields and batch sizes fluctuate, and the size of each lot almost definitely varies by some amount.

And all adverse events are reported to the manufacturer with the lot number (if available), mandatorily by law. Claiming lot outcomes are intentionally made difficult to discern is an outright lie.